Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease
Changes in metabolites detected by proton magnetic resonance spectroscopy (1H MRS) of the brain have been demonstrated in Alzheimer’s disease. Our objectives were, first, longitudinally to measure absolute concentrations of metabolites in both hippocampi, the sites of early Alzheimer’s disease, in p...
Gespeichert in:
Veröffentlicht in: | Brain (London, England : 1878) England : 1878), 2002-10, Vol.125 (10), p.2332-2341 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2341 |
---|---|
container_issue | 10 |
container_start_page | 2332 |
container_title | Brain (London, England : 1878) |
container_volume | 125 |
creator | Dixon, Ruth M. Bradley, Kevin M. Budge, Marc M. Styles, Peter Smith, A. David |
description | Changes in metabolites detected by proton magnetic resonance spectroscopy (1H MRS) of the brain have been demonstrated in Alzheimer’s disease. Our objectives were, first, longitudinally to measure absolute concentrations of metabolites in both hippocampi, the sites of early Alzheimer’s disease, in patients with clinical Alzheimer’s disease and controls; secondly, to separate the relative contribution of atrophy and metabolite concentration change to overall signal change; and, thirdly, to determine whether metabolite concentrations in the hippocampus relate to cognitive scores. 1H MR spectra were acquired from a single voxel (12 × 15 × 25 mm3 = 4.5 ml) aligned to the long axis of each hippocampus in nine probable or possible Alzheimer’s disease subjects diagnosed according to the National Institute of Neurologic and Cognitive Disorders and Stroke (NINCDS) compared with 14 age‐matched NINCDS‐negative Alzheimer’s disease controls. Metabolite concentrations were corrected for the amount of CSF present in the voxel. Hippocampal volumes were measured at the same time. The same protocol was repeated approximately 1 year later. We found that atrophy‐ corrected hippocampal N‐acetylaspartate (NAA) concentration was lower in cognitively impaired subjects compared with controls. This was significant for the left hippocampus (baseline 87% of control, P = 0.013; and at 1 year 76% of control, P = 0.020). Hippocampal volumes also differed significantly between the groups, and decreased significantly over 1 year in the Alzheimer’s disease group (12%, P = 0.017). The decrease in [NAA] over 1 year was not significant in either group. Discriminant analysis revealed that the best classification of subjects was by including both left NAA concentration and left hippocampal volume. myo‐Inositol signals from these small voxels had poor signal‐to‐noise and demonstrated no significant changes. We conclude that 1HMRS‐detectable metabolites can be quantified from the hippocampi of cognitively impaired individuals, and that hippocampal [NAA] is significantly reduced in Alzheimer’s disease, in excess of atrophy. In our cohort, the differences were more significant for the left hippocampus. |
doi_str_mv | 10.1093/brain/awf226 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72115610</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72115610</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-7f4610984a09625a15e8877add1ae641cdd16e4d5bb7208ddada3d1000d92a503</originalsourceid><addsrcrecordid>eNqF0U1rFDEYB_BBFLut3jxLEOzJsUkmLzPHslgrLHioL8VLeDbJdFNnkmmSUevJr-HX85OYdRcLXjzlgfx44Pn_q-oJwS8J7pqTdQTnT-BrT6m4Vy0IE7imhIv71QJjLOq24_igOkzpGmPCGioeVgeEUsZw2y2qYRX8lcuzcR4GdDODzy5Ddl8smmLIwaMRrrzNTqNoU_DgtUVpsjrHkHSYblHoUd5YtHHTFDSM05yQ8-h0-L6xbrTx14-fCRmXLCT7qHrQw5Ds4_17VL0_e_VueV6v3r5-szxd1ZpxkmvZM1FOaxngTlAOhNu2lRKMIWAFI7oMwjLD12tJcWsMGGgMKdeajgLHzVF1vNtbTriZbcpqdEnbYQBvw5yUpKQERP4PScd41xFZ4LN_4HWYY4lsazijAuMterFDumSTou3VFN0I8VYRrLZdqT9dqV1XhT_d75zXozV3eF9OAc_3AJKGoY8lfJfuXNNRKdl2Ub1zLmX77e8_xM9KyEZydX75SV3wyw_Lj2cXSjS_AUzgr-g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195426007</pqid></control><display><type>article</type><title>Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Dixon, Ruth M. ; Bradley, Kevin M. ; Budge, Marc M. ; Styles, Peter ; Smith, A. David</creator><creatorcontrib>Dixon, Ruth M. ; Bradley, Kevin M. ; Budge, Marc M. ; Styles, Peter ; Smith, A. David</creatorcontrib><description>Changes in metabolites detected by proton magnetic resonance spectroscopy (1H MRS) of the brain have been demonstrated in Alzheimer’s disease. Our objectives were, first, longitudinally to measure absolute concentrations of metabolites in both hippocampi, the sites of early Alzheimer’s disease, in patients with clinical Alzheimer’s disease and controls; secondly, to separate the relative contribution of atrophy and metabolite concentration change to overall signal change; and, thirdly, to determine whether metabolite concentrations in the hippocampus relate to cognitive scores. 1H MR spectra were acquired from a single voxel (12 × 15 × 25 mm3 = 4.5 ml) aligned to the long axis of each hippocampus in nine probable or possible Alzheimer’s disease subjects diagnosed according to the National Institute of Neurologic and Cognitive Disorders and Stroke (NINCDS) compared with 14 age‐matched NINCDS‐negative Alzheimer’s disease controls. Metabolite concentrations were corrected for the amount of CSF present in the voxel. Hippocampal volumes were measured at the same time. The same protocol was repeated approximately 1 year later. We found that atrophy‐ corrected hippocampal N‐acetylaspartate (NAA) concentration was lower in cognitively impaired subjects compared with controls. This was significant for the left hippocampus (baseline 87% of control, P = 0.013; and at 1 year 76% of control, P = 0.020). Hippocampal volumes also differed significantly between the groups, and decreased significantly over 1 year in the Alzheimer’s disease group (12%, P = 0.017). The decrease in [NAA] over 1 year was not significant in either group. Discriminant analysis revealed that the best classification of subjects was by including both left NAA concentration and left hippocampal volume. myo‐Inositol signals from these small voxels had poor signal‐to‐noise and demonstrated no significant changes. We conclude that 1HMRS‐detectable metabolites can be quantified from the hippocampi of cognitively impaired individuals, and that hippocampal [NAA] is significantly reduced in Alzheimer’s disease, in excess of atrophy. In our cohort, the differences were more significant for the left hippocampus.</description><identifier>ISSN: 0006-8950</identifier><identifier>ISSN: 1460-2156</identifier><identifier>EISSN: 1460-2156</identifier><identifier>DOI: 10.1093/brain/awf226</identifier><identifier>PMID: 12244089</identifier><identifier>CODEN: BRAIAK</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>1H MRS = proton magnetic resonance spectroscopy ; Aged ; Aged, 80 and over ; Alzheimer Disease - pathology ; Alzheimer Disease - psychology ; Biological and medical sciences ; CAMCOG = Cambridge cognitive examination ; Cho = choline ; Cr = creatine ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; dementia ; Female ; Hippocampus - pathology ; Humans ; Longitudinal Studies ; Magnetic Resonance Spectroscopy - methods ; Magnetic Resonance Spectroscopy - statistics & numerical data ; Male ; medial temporal lobe ; Medical sciences ; Middle Aged ; MI = myo‐inositol ; MMSE = Mini‐Mental State Examination ; NAA = N‐acetylaspartate ; neurodegeneration ; Neurology ; NINCDS = National Institute of Neurologic and Cognitive Disorders and Stroke ; proton MRS ; Protons ; Statistics, Nonparametric</subject><ispartof>Brain (London, England : 1878), 2002-10, Vol.125 (10), p.2332-2341</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Oct 2002</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-7f4610984a09625a15e8877add1ae641cdd16e4d5bb7208ddada3d1000d92a503</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13927746$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12244089$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dixon, Ruth M.</creatorcontrib><creatorcontrib>Bradley, Kevin M.</creatorcontrib><creatorcontrib>Budge, Marc M.</creatorcontrib><creatorcontrib>Styles, Peter</creatorcontrib><creatorcontrib>Smith, A. David</creatorcontrib><title>Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease</title><title>Brain (London, England : 1878)</title><addtitle>Brain</addtitle><description>Changes in metabolites detected by proton magnetic resonance spectroscopy (1H MRS) of the brain have been demonstrated in Alzheimer’s disease. Our objectives were, first, longitudinally to measure absolute concentrations of metabolites in both hippocampi, the sites of early Alzheimer’s disease, in patients with clinical Alzheimer’s disease and controls; secondly, to separate the relative contribution of atrophy and metabolite concentration change to overall signal change; and, thirdly, to determine whether metabolite concentrations in the hippocampus relate to cognitive scores. 1H MR spectra were acquired from a single voxel (12 × 15 × 25 mm3 = 4.5 ml) aligned to the long axis of each hippocampus in nine probable or possible Alzheimer’s disease subjects diagnosed according to the National Institute of Neurologic and Cognitive Disorders and Stroke (NINCDS) compared with 14 age‐matched NINCDS‐negative Alzheimer’s disease controls. Metabolite concentrations were corrected for the amount of CSF present in the voxel. Hippocampal volumes were measured at the same time. The same protocol was repeated approximately 1 year later. We found that atrophy‐ corrected hippocampal N‐acetylaspartate (NAA) concentration was lower in cognitively impaired subjects compared with controls. This was significant for the left hippocampus (baseline 87% of control, P = 0.013; and at 1 year 76% of control, P = 0.020). Hippocampal volumes also differed significantly between the groups, and decreased significantly over 1 year in the Alzheimer’s disease group (12%, P = 0.017). The decrease in [NAA] over 1 year was not significant in either group. Discriminant analysis revealed that the best classification of subjects was by including both left NAA concentration and left hippocampal volume. myo‐Inositol signals from these small voxels had poor signal‐to‐noise and demonstrated no significant changes. We conclude that 1HMRS‐detectable metabolites can be quantified from the hippocampi of cognitively impaired individuals, and that hippocampal [NAA] is significantly reduced in Alzheimer’s disease, in excess of atrophy. In our cohort, the differences were more significant for the left hippocampus.</description><subject>1H MRS = proton magnetic resonance spectroscopy</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - pathology</subject><subject>Alzheimer Disease - psychology</subject><subject>Biological and medical sciences</subject><subject>CAMCOG = Cambridge cognitive examination</subject><subject>Cho = choline</subject><subject>Cr = creatine</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>dementia</subject><subject>Female</subject><subject>Hippocampus - pathology</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Magnetic Resonance Spectroscopy - methods</subject><subject>Magnetic Resonance Spectroscopy - statistics & numerical data</subject><subject>Male</subject><subject>medial temporal lobe</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>MI = myo‐inositol</subject><subject>MMSE = Mini‐Mental State Examination</subject><subject>NAA = N‐acetylaspartate</subject><subject>neurodegeneration</subject><subject>Neurology</subject><subject>NINCDS = National Institute of Neurologic and Cognitive Disorders and Stroke</subject><subject>proton MRS</subject><subject>Protons</subject><subject>Statistics, Nonparametric</subject><issn>0006-8950</issn><issn>1460-2156</issn><issn>1460-2156</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U1rFDEYB_BBFLut3jxLEOzJsUkmLzPHslgrLHioL8VLeDbJdFNnkmmSUevJr-HX85OYdRcLXjzlgfx44Pn_q-oJwS8J7pqTdQTnT-BrT6m4Vy0IE7imhIv71QJjLOq24_igOkzpGmPCGioeVgeEUsZw2y2qYRX8lcuzcR4GdDODzy5Ddl8smmLIwaMRrrzNTqNoU_DgtUVpsjrHkHSYblHoUd5YtHHTFDSM05yQ8-h0-L6xbrTx14-fCRmXLCT7qHrQw5Ds4_17VL0_e_VueV6v3r5-szxd1ZpxkmvZM1FOaxngTlAOhNu2lRKMIWAFI7oMwjLD12tJcWsMGGgMKdeajgLHzVF1vNtbTriZbcpqdEnbYQBvw5yUpKQERP4PScd41xFZ4LN_4HWYY4lsazijAuMterFDumSTou3VFN0I8VYRrLZdqT9dqV1XhT_d75zXozV3eF9OAc_3AJKGoY8lfJfuXNNRKdl2Ub1zLmX77e8_xM9KyEZydX75SV3wyw_Lj2cXSjS_AUzgr-g</recordid><startdate>20021001</startdate><enddate>20021001</enddate><creator>Dixon, Ruth M.</creator><creator>Bradley, Kevin M.</creator><creator>Budge, Marc M.</creator><creator>Styles, Peter</creator><creator>Smith, A. David</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20021001</creationdate><title>Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease</title><author>Dixon, Ruth M. ; Bradley, Kevin M. ; Budge, Marc M. ; Styles, Peter ; Smith, A. David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-7f4610984a09625a15e8877add1ae641cdd16e4d5bb7208ddada3d1000d92a503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>1H MRS = proton magnetic resonance spectroscopy</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - pathology</topic><topic>Alzheimer Disease - psychology</topic><topic>Biological and medical sciences</topic><topic>CAMCOG = Cambridge cognitive examination</topic><topic>Cho = choline</topic><topic>Cr = creatine</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>dementia</topic><topic>Female</topic><topic>Hippocampus - pathology</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Magnetic Resonance Spectroscopy - methods</topic><topic>Magnetic Resonance Spectroscopy - statistics & numerical data</topic><topic>Male</topic><topic>medial temporal lobe</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>MI = myo‐inositol</topic><topic>MMSE = Mini‐Mental State Examination</topic><topic>NAA = N‐acetylaspartate</topic><topic>neurodegeneration</topic><topic>Neurology</topic><topic>NINCDS = National Institute of Neurologic and Cognitive Disorders and Stroke</topic><topic>proton MRS</topic><topic>Protons</topic><topic>Statistics, Nonparametric</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dixon, Ruth M.</creatorcontrib><creatorcontrib>Bradley, Kevin M.</creatorcontrib><creatorcontrib>Budge, Marc M.</creatorcontrib><creatorcontrib>Styles, Peter</creatorcontrib><creatorcontrib>Smith, A. David</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Brain (London, England : 1878)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dixon, Ruth M.</au><au>Bradley, Kevin M.</au><au>Budge, Marc M.</au><au>Styles, Peter</au><au>Smith, A. David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease</atitle><jtitle>Brain (London, England : 1878)</jtitle><addtitle>Brain</addtitle><date>2002-10-01</date><risdate>2002</risdate><volume>125</volume><issue>10</issue><spage>2332</spage><epage>2341</epage><pages>2332-2341</pages><issn>0006-8950</issn><issn>1460-2156</issn><eissn>1460-2156</eissn><coden>BRAIAK</coden><abstract>Changes in metabolites detected by proton magnetic resonance spectroscopy (1H MRS) of the brain have been demonstrated in Alzheimer’s disease. Our objectives were, first, longitudinally to measure absolute concentrations of metabolites in both hippocampi, the sites of early Alzheimer’s disease, in patients with clinical Alzheimer’s disease and controls; secondly, to separate the relative contribution of atrophy and metabolite concentration change to overall signal change; and, thirdly, to determine whether metabolite concentrations in the hippocampus relate to cognitive scores. 1H MR spectra were acquired from a single voxel (12 × 15 × 25 mm3 = 4.5 ml) aligned to the long axis of each hippocampus in nine probable or possible Alzheimer’s disease subjects diagnosed according to the National Institute of Neurologic and Cognitive Disorders and Stroke (NINCDS) compared with 14 age‐matched NINCDS‐negative Alzheimer’s disease controls. Metabolite concentrations were corrected for the amount of CSF present in the voxel. Hippocampal volumes were measured at the same time. The same protocol was repeated approximately 1 year later. We found that atrophy‐ corrected hippocampal N‐acetylaspartate (NAA) concentration was lower in cognitively impaired subjects compared with controls. This was significant for the left hippocampus (baseline 87% of control, P = 0.013; and at 1 year 76% of control, P = 0.020). Hippocampal volumes also differed significantly between the groups, and decreased significantly over 1 year in the Alzheimer’s disease group (12%, P = 0.017). The decrease in [NAA] over 1 year was not significant in either group. Discriminant analysis revealed that the best classification of subjects was by including both left NAA concentration and left hippocampal volume. myo‐Inositol signals from these small voxels had poor signal‐to‐noise and demonstrated no significant changes. We conclude that 1HMRS‐detectable metabolites can be quantified from the hippocampi of cognitively impaired individuals, and that hippocampal [NAA] is significantly reduced in Alzheimer’s disease, in excess of atrophy. In our cohort, the differences were more significant for the left hippocampus.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>12244089</pmid><doi>10.1093/brain/awf226</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-8950 |
ispartof | Brain (London, England : 1878), 2002-10, Vol.125 (10), p.2332-2341 |
issn | 0006-8950 1460-2156 1460-2156 |
language | eng |
recordid | cdi_proquest_miscellaneous_72115610 |
source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals |
subjects | 1H MRS = proton magnetic resonance spectroscopy Aged Aged, 80 and over Alzheimer Disease - pathology Alzheimer Disease - psychology Biological and medical sciences CAMCOG = Cambridge cognitive examination Cho = choline Cr = creatine Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases dementia Female Hippocampus - pathology Humans Longitudinal Studies Magnetic Resonance Spectroscopy - methods Magnetic Resonance Spectroscopy - statistics & numerical data Male medial temporal lobe Medical sciences Middle Aged MI = myo‐inositol MMSE = Mini‐Mental State Examination NAA = N‐acetylaspartate neurodegeneration Neurology NINCDS = National Institute of Neurologic and Cognitive Disorders and Stroke proton MRS Protons Statistics, Nonparametric |
title | Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T17%3A57%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longitudinal%20quantitative%20proton%20magnetic%20resonance%20spectroscopy%20of%20the%20hippocampus%20in%20Alzheimer%E2%80%99s%20disease&rft.jtitle=Brain%20(London,%20England%20:%201878)&rft.au=Dixon,%20Ruth%20M.&rft.date=2002-10-01&rft.volume=125&rft.issue=10&rft.spage=2332&rft.epage=2341&rft.pages=2332-2341&rft.issn=0006-8950&rft.eissn=1460-2156&rft.coden=BRAIAK&rft_id=info:doi/10.1093/brain/awf226&rft_dat=%3Cproquest_cross%3E72115610%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195426007&rft_id=info:pmid/12244089&rfr_iscdi=true |